Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the stocks with explosive growth potential. On February 19, Madrigal Pharmaceuticals announced the earnings report for 2025, which was driven by the successful launch of Rezdiffra, the first approved treatment for MASH. Full-year net sales reached $958.4 million, with Q4 revenue alone hitting $321.1 million, more than tripling the previous year’s quarterly results. By the end of 2025, the patient base on Rezdiffra grew to over 36,250, up from ~29,500 in Q3.

The company significantly evolved from a single-product entity into a diversified biopharmaceutical leader with a pipeline of more than 10 programs. Key strategic expansions include licensing an oral GLP-1 receptor agonist, a Phase 2 oral DGAT-2 inhibitor called ervogastat, and six preclinical siRNA programs. These assets are intended to create combination therapies anchored by Rezdiffra to address various patient subtypes and genetic drivers of MASH. Additionally, Madrigal secured long-term market exclusivity for Rezdiffra through a patent extension lasting until 2045 and initiated its international rollout with a launch in Germany.

Looking toward 2026, Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) expects continued double-digit growth in the MASH market despite rising gross-to-net impacts, which are projected to reach the high 30% range. While the international contribution remained negligible in 2025, the US market remains the primary growth engine with broad first-line insurance access and steady patient starts. The company is also focused on clinical milestones, particularly the MAESTRO-NASH outcomes trial in cirrhosis patients, which is on track to deliver data in 2027.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is a biopharmaceutical company that delivers novel therapeutics for metabolic dysfunction-associated steatohepatitis/MASH in the US.

While we acknowledge the potential of MDGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Stocks for Beginners with Little Money in 2026.

Disclosure: None. Follow Insider Monkey on Google News.